Danavorexton

Danavorexton
Clinical data
Other namesTAK-925
Routes of
administration		Intravenous
Drug classOrexin receptor agonist
Identifiers
IUPAC name
  • methyl (2R,3S)-3-(methanesulfonamido)-2-[(4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H32N2O5S
Molar mass424.56 g·mol−1
3D model (JSmol)
SMILES
  • COC(=O)N1CCC[C@@H]([C@@H]1COC2CCC(CC2)C3=CC=CC=C3)NS(=O)(=O)C
InChI
  • InChI=1S/C21H32N2O5S/c1-27-21(24)23-14-6-9-19(22-29(2,25)26)20(23)15-28-18-12-10-17(11-13-18)16-7-4-3-5-8-16/h3-5,7-8,17-20,22H,6,9-15H2,1-2H3/t17?,18?,19-,20-/m0/s1
  • Key:UXZAJSZFFARTEI-GUMHCPJTSA-N

Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist. As of March 2021, danavorexton is under investigation for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea.[1][2]

See also

References

  1. ↑ "Danavorexton - Takeda". Adis Insight. Springer Nature Switzerland AG. Retrieved 7 March 2021.
  2. ↑ Evans R, Tanaka S, Tanaka S, Touno S, Shimizu K, Sakui S, et al. (December 2019). "A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes". Sleep Medicine. 64: S105–S106. doi:10.1016/j.sleep.2019.11.290.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.